Disclosed herein are fused bicyclic thiazole compounds of formula (I), wherein the substituents are as defined in the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) and as such are useful in the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors are involved, e.g.: neurological or psychiatric disorders schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychosis associated with dementia, major depressive disorder. Examples of particularly preferred compounds include: 6,7-dihydro-2-(phenoxymethyl)-5-[(tetrahydro-2H-pyran-4-yl)methyl]thiazolo[5,4-c]pyridin-4(5H)-one 6,7-dihydro-5-(2-methoxyethyl)-2-(phenoxymethyl)-thiazolo[5,4-c]pyridin-4(5H)-one 5,6,7,8-tetrahydro-2-(phenoxymethy1)-4H-thiazolo[5,4-c]azepin-4-one 5-(4-fluoropheny1)-5,6,7,8-tetrahydro-2-(phenoxymethy1)-4H-thiazolo[5,4-c]azepin-4-one 5-(2,4-difluoropheny1)-2-[(3-fluorophenoxy)methy1]-6,7-dihydro-thiazolo[5,4-c]pyridin-4(5H)-one, 5-cyclopropy1-6,7-dihydro-2-(phenoxymethy1)-thiazolo[5,4-c]pyridin-4(5H)-one 2-[(3-fluorophenoxy)methy1]-5-(5-fluoro-2-pyridiny1)-6,7-dihydro-thiazolo[5,4-c]pyridin-4(5H)-one.